BC Innovations | Nov 26, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Peptides; polymers An amphiphilic dendrimer-peptide construct could be used for tumor-targeted delivery of siRNA therapies. The construct has four components: an amphiphilic dendrimer complex for loading with siRNA cargo; a peptide composed of repeating...
BC Innovations | Apr 24, 2018
Distillery Therapeutics


INDICATION: Myeloproliferative disorder Patient sample and mouse studies suggest inhibiting Hsp27 could help treat myelofibrosis (MF). In serum samples and circulating hematopoietic progenitor cells from patients with myeloproliferative neoplasm (MPN)-associated MF, levels of Hsp27 were...
BC Innovations | Aug 24, 2017
Translation in Brief

Unclumping TDP-43

Two studies published in Nature Communications have identified different features of TDP-43 that promote its aggregation in neurodegenerative disorders, and point to different therapeutic strategies for preventing or dissolving the clumps. Aggregation of TAR DNA...
BC Week In Review | Nov 10, 2016
Clinical News

Apatorsen: Final Ph II data

Final data from the investigator-led, open-label, U.S. Phase II Borealis-2 trial in 200 patients with metastatic bladder cancer whose disease progressed following first-line, platinum-based chemotherapy showed that once-weekly 600 mg IV apatorsen plus docetaxel met...
BC Innovations | Sep 29, 2016
Distillery Techniques

Techniques: Panel of 12 hippocampal proteins to diagnose early stage Alzheimer's disease

Biomarkers TECHNOLOGY: Tissue markers Hippocampal expression of a panel of 12 proteins could help diagnose early stage AD. Microarray analyses of postmortem brain tissue samples from six individuals previously not diagnosed with AD identified associations...
BioCentury | Apr 4, 2016

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Yrs cash pre-cut Cash date 12-mo op loss ended 12/31 1/7/16 Sequenom Inc. (NASDAQ:SQNM) 20% to 390 $76.2 9.65 12/31/15 $7.9 Sequenom restructured to focus on women's health...
BC Week In Review | Feb 15, 2016
Company News

OncoGenex cancer news

OncoGenex will reduce headcount by 11 (27%) to 30 to focus on reaching several near-term clinical milestones for custirsen and apatorsen. The company expects cost savings from the headcount reduction, plus the elimination of expenditures...
BC Week In Review | Jan 25, 2016
Clinical News

Apatorsen: Phase II data

The double-blind, U.S. Phase II Spruce trial in about 155 patients with previously untreated metastatic non-squamous NSCLC showed that once-weekly 600 mg IV apatorsen plus carboplatin and Alimta pemetrexed missed the primary endpoint of improving...
BC Week In Review | Dec 21, 2015
Clinical News

Apatorsen: Phase II ongoing

OncoGenex said an independent DSMB recommended continuation of the investigator-led, open-label, U.S. Phase II Borealis-2 trial comparing 600 mg IV apatorsen on days 1, 8 and 15 plus IV docetaxel on day 1 of a...
BC Innovations | Nov 12, 2015
Product R&D

Crystallin-clear ViewPoint

By exploring the biophysics of proteins with disease-associated mutations, a UCSF group has developed a way to screen for drugs that rescue the activity of non-enzymatic targets, and proved its value with molecular chaperones. After...
Items per page:
1 - 10 of 51